Tags : TJ202/MOR202

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients

Shots: The first P-II NCT03860038 trial involves assessing of TJ202/MOR202 as a 3L treatment in patients with R/R MM while the second P-II trial assess TJ202/MOR202 + lenalidomide (LEN) + dexamethasone (DEX) vs LEN + DEX in 1L R/R MM In 2017, I-Mab in-licensed TJ202/MOR202 from MorphoSys while holds exclusive rights to develop and commercialize […]Read More